孕36周眼动脉多普勒预测子痫前期:既往模型的验证与更新
本研究为前瞻性验证研究,在6746例单胎妊娠35+0至36+6周孕妇中验证眼动脉收缩期峰值流速比值预测子痫前期的模型,并与既往2287例训练数据合并更新模型参数;联合母体因素、MAP、UtA-PI、PlGF、sFlt-1及PSV比值在10%假阳性率下对3周内和任何时间分娩子痫前期的检出率分别为85.0%和65.7%。
要点
- 孕35-37周眼动脉PSV比值联合其他生物标志物可有效预测子痫前期。
- 联合模型在10%假阳性率下3周内子痫前期检出率为85.0%。
- 生物物理检测优于单独低PlGF或高sFlt-1/PlGF比值,但与生化检测无显著差异。
核心结论
- 孕35-37周母体眼动脉PSV比值联合其他生物标志物可有效预测子痫前期的后续发生。
研究设计与样本
- 前瞻性验证研究,纳入6746例单胎妊娠孕妇,于35+0至36+6周进行常规筛查。
- 验证数据集与既往用于模型开发的2287例训练数据集合并,用于更新原模型参数。
- 子痫前期定义依据2019年美国妇产科医师学会标准。
主要发现
- 验证数据集中,母体因素联合PSV比值筛查3周内及任何时间分娩子痫前期的性能与训练数据集一致,预测与观察发生率吻合良好。
- 合并数据中,母体因素、MAP、UtA-PI、PlGF、sFlt-1及PSV比值联合筛查在10%假阳性率下,3周内分娩子痫前期检出率为85.0%(95% CI 76.5-91.4%),任何时间分娩子痫前期检出率为65.7%(95% CI 59.2-71.7%)。
- 生物物理检测(母体因素、MAP、UtA-PI及PSV比值)性能优于低PlGF浓度(<第10百分位)或高sFlt-1/PlGF浓度比值(>第90百分位)筛查,但与生化检测(母体因素联合PlGF和sFlt-1)在3周内及任何时间子痫前期预测上无显著差异。
关键数值与推荐
- 筛查阳性率固定为10%时,联合模型对3周内分娩子痫前期的检出率为85.0%(95% CI 76.5-91.4%)。
- 筛查阳性率固定为10%时,联合模型对任何时间分娩子痫前期的检出率为65.7%(95% CI 59.2-71.7%)。
- 低PlGF浓度定义为<第10百分位,高sFlt-1/PlGF浓度比值定义为>第90百分位。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate and extend a model incorporating maternal ophthalmic artery Doppler at 35-37 weeks' gestation in the prediction of subsequent development of pre-eclampsia (PE). METHODS: This was a prospective validation study of screening for PE (defined according to the 2019 American College of Obstetricians and Gynecologists criteria) by maternal ophthalmic artery peak systolic velocity (PSV) ratio in 6746 singleton pregnancies undergoing routine care at 35 + 0 to 36 + 6 weeks' gestation (validation dataset). Additionally, the data from the validation dataset were combined with those of 2287 pregnancies that were previously used for development of the model (training dataset), and the combined data were used to update the original model parameters. The competing-risks model was used to estimate the individual patient-specific risk of delivery with PE at any time and within 3 weeks from assessment by a combination of maternal demographic characteristics and medical history with PSV ratio alone and in combination with the established PE biomarkers of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1). We evaluated the predictive performance of the model by examining, first, the ability to discriminate between the PE and non-PE groups using the area under the receiver-operating-characteristics curve and the detection rate (DR) at fixed screen-positive (SPR) and false-positive rates of 10% and, second, calibration by measuring the calibration slope and calibration-in-the-large. McNemar's test was used to compare the performance of screening by a biophysical test (maternal factors, MAP, UtA-PI and PSV ratio) vs a biochemical test (maternal factors, PlGF and sFlt-1), low PlGF concentration (< 10th percentile) or high sFlt-1/PlGF concentration ratio (> 90th percentile). RESULTS: In the validation dataset, the performance of screening by maternal factors and PSV ratio for delivery with PE within 3 weeks and at any time after assessment was consistent with that in the training dataset, and there was good agreement between the predicted and observed incidence of PE. In the combined data from the training and validation datasets, good prediction for PE was achieved in screening by a combination of maternal factors, MAP, UtA-PI, PlGF, sFlt-1 and PSV ratio, with a DR, at a 10% SPR, of 85.0% (95% CI, 76.5-91.4%) for delivery with PE within 3 weeks and 65.7% (95% CI, 59.2-71.7%) for delivery with PE at any time after assessment. The performance of a biophysical test was superior to that of screening by low PlGF concentration or high sFlt-1/PlGF concentration ratio but not significantly different from the performance of a biochemical test combining maternal factors with PlGF and sFlt-1 for both PE within 3 weeks and PE at any time after assessment. CONCLUSION: Maternal ophthalmic artery PSV ratio at 35-37 weeks' gestation in combination with other biomarkers provides effective prediction of subsequent development of PE. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Mansukhani T, Wright A, Arechvo A, et al. Ophthalmic artery Doppler at 36 weeks' gestation in prediction of pre-eclampsia: validation and update of previous model. Ultrasound Obstet Gynecol. 2024. PMID: 37616530. doi:10.1002/uog.27464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。